Dr. Hai Li is a Senior Scientist specializing in cellular and molecular biology, focusing on gene editing, engineered immune cells, and other mammalian cell lines for drug development and cancer immunotherapy.
Dr. Li holds a Ph.D. in Cellular and Molecular Biology from Université Claude Bernard Lyon 1.
Dr. Li engineered allogeneic T cells at Sana Biotechnology using CRISPR/Cas technology and the AAV virus. He also developed assays for detecting gene mutations in live iPSCs. Prior to Sana, Dr. Li worked as a scientist at Bolt Biotherapeutics, generating cancer cell lines and conducting genome editing to explore antibody-drug conjugate mechanisms. Prior to Bolt Biotherapeutics, Dr. Li focused on dual-targeted CAR and TCR-engineered T cells and optimized non-viral CAR T cell production. Dr. Li’s early research experience includes a research scientist position at Stanford University School of Medicine and the VA Palo Alto Health Care System, where they contributed to pioneering studies in cellular biology and cancer research.
Dr. Li’s research centers on innovative immunotherapeutic strategies and advancing gene editing technologies to improve cancer treatment.
With extensive experience and a commitment to scientific advancement, Dr. Hai Li is dedicated to transforming oncology through cutting-edge research.
